The greatest biological diversity on the planet, combined with advanced science and the current legal framework in Brazil, offers a unique opportunity for the development of innovative treatments for unmet global medical needs..
Created in 2012 to operate in the biopharmaceuticals segment, Bionovis S.A. is a company controlled by four Brazilian laboratories, including Aché. The company works in partnership with Bio-Manguinhos through PDPs (Productive Development Partnership) to produce highly complex biological drugs. It has six PDPs already in Phase III: Infliximab, Betainterferona 1a, Etanercept, Golimumab, Rituximab and Trastuzumab. Among the highlights was the start of the supply of Golimumab, Rituximab and Trastuzumab to the Ministry of Health through PDPs.
An industrial scale industrial unit is under construction in Valinhos, SP for producing API (active pharmaceutical ingredient), and formulating, filling, packaging and storing biological drugs. This unit will have temperaturecontrolled warehouses, R&D laboratories, quality control laboratories, a pilot plant and a manufacturing plant with production lines capable of absorbing and implementing technologies on an industrial scale.